a modern biotechnology company, responsible for developing one of the vaccines used in United State, announced preliminary figures for the effects of booster doses of an immunizing agent in the fight against micron variable This Monday (20).
“The currently authorized enhancer of 50 μg mRNA-1273 increased levels of neutralizing antibodies against Micron by about 37 times compared to pre-Post levels,” the company said.
Protection levels can rise significantly if the dose is doubled. “A 100-mcg dose of mRNA-1273 increased neutralizing antibody levels approximately 83-fold compared to pre-Post levels,” Moderna said in a statement.
Neutralization of Ômicron antibodies was evaluated in a pseudovirus neutralization titer (ID50) test (PsVNT) performed in laboratories established by the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) at Duke University Medical Center.
All groups had low levels of neutralizing antibodies in the Omicron PsVNT assay before boosting.
Moderna also announced that it will continue to develop a specific vaccine for the micronized variant and that it expects to advance clinical trials in early 2022.
“To respond to this highly transmissible variant, Moderna will continue to rapidly advance a micron-specific booster candidate for clinical trials, should the need arise in the future,” said Stefan Bancel, Moderna CEO.
“We will also continue to create and share data on our strengthening strategies with public health authorities to help them make evidence-based decisions about the best SARS-CoV-2 vaccination strategies,” the executive adds.
“Music fanatic. Professional problem solver. Reader. Award-winning tv ninja.”